5,464 Shares in Corcept Therapeutics Incorporated (NASDAQ:CORT) Acquired by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft purchased a new position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 5,464 shares of the biotechnology company's stock, valued at approximately $624,000.

Several other hedge funds have also recently modified their holdings of CORT. Vanguard Group Inc. boosted its stake in Corcept Therapeutics by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 10,115,624 shares of the biotechnology company's stock worth $509,726,000 after purchasing an additional 109,294 shares during the last quarter. Parallel Advisors LLC lifted its stake in shares of Corcept Therapeutics by 3.7% in the first quarter. Parallel Advisors LLC now owns 3,972,416 shares of the biotechnology company's stock worth $453,729,000 after buying an additional 142,784 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its position in Corcept Therapeutics by 12.5% during the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,376,881 shares of the biotechnology company's stock worth $69,381,000 after acquiring an additional 153,100 shares during the last quarter. Northern Trust Corp boosted its position in Corcept Therapeutics by 10.2% during the fourth quarter. Northern Trust Corp now owns 1,015,515 shares of the biotechnology company's stock worth $51,172,000 after acquiring an additional 94,128 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. grew its stake in Corcept Therapeutics by 12.5% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 886,576 shares of the biotechnology company's stock valued at $44,675,000 after acquiring an additional 98,512 shares in the last quarter. Institutional investors and hedge funds own 93.61% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on CORT. Piper Sandler decreased their target price on shares of Corcept Therapeutics from $131.00 to $121.00 and set an "overweight" rating on the stock in a research note on Friday. Wall Street Zen lowered Corcept Therapeutics from a "buy" rating to a "hold" rating in a research note on Wednesday, May 14th. HC Wainwright dropped their target price on Corcept Therapeutics from $150.00 to $145.00 and set a "buy" rating for the company in a report on Tuesday, May 6th. Canaccord Genuity Group cut their target price on Corcept Therapeutics from $142.00 to $137.00 and set a "buy" rating for the company in a research note on Friday. Finally, Truist Financial set a $135.00 price target on shares of Corcept Therapeutics in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $134.50.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider Sean Maduck sold 473 shares of the stock in a transaction dated Friday, July 18th. The shares were sold at an average price of $73.44, for a total transaction of $34,737.12. Following the completion of the transaction, the insider owned 17,705 shares of the company's stock, valued at $1,300,255.20. This trade represents a 2.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joseph K. Belanoff sold 615 shares of Corcept Therapeutics stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $73.69, for a total transaction of $45,319.35. Following the sale, the chief executive officer owned 2,901,370 shares of the company's stock, valued at approximately $213,801,955.30. This represents a 0.02% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 173,038 shares of company stock worth $13,237,621 in the last 90 days. Insiders own 20.80% of the company's stock.

Corcept Therapeutics Price Performance

CORT traded up $1.83 during trading hours on Friday, reaching $69.00. The company's stock had a trading volume of 2,107,375 shares, compared to its average volume of 1,377,384. The stock has a market cap of $7.32 billion, a PE ratio of 59.48 and a beta of 0.15. Corcept Therapeutics Incorporated has a fifty-two week low of $32.33 and a fifty-two week high of $117.33. The business's 50-day moving average is $71.81 and its 200-day moving average is $68.21.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last posted its earnings results on Thursday, July 31st. The biotechnology company reported $0.29 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.06. Corcept Therapeutics had a return on equity of 20.40% and a net margin of 19.33%. The company had revenue of $194.43 million for the quarter, compared to the consensus estimate of $199.40 million. During the same quarter in the previous year, the business earned $0.32 earnings per share. The company's revenue for the quarter was up 18.7% on a year-over-year basis. Analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current year.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.